1. Scrip
  2. >>COVID-19

ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations

Panel Recommends Janssen Vaccine A Day After EUA

 
• By Sue Sutter

The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.  

Bus on country road
One speaker at the ACIP meeting worried about a perception of inferiority if the single-dose Janssen vaccine is destined for places where people have had access issues. • Source: Shutterstock

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will not compare efficacy and safety across the authorized COVID-19 vaccines, at least in the near term, panel chairman Jose Romero said.

During an emergency meeting on 28 February, ACIP voted 12-0, with one recusal, to recommend vaccination with Janssen Biotech Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.